Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.

Kim, S-M; Kim, H; Yun, M R; Kang, H N; Pyo, K-H; Park, H J; Lee, J M; Choi, H M; Ellinghaus, P; Ocker, M; Paik, S; Kim, H R; Cho, B C

Kim, S-M; Kim, H; Yun, M R; Kang, H N; Pyo, K-H; Park, H J; Lee, J M; Choi, H M; Ellinghaus, P; Ocker, M; Paik, S; Kim, H R; Cho, B C.

Afiliación

Kim SM; JE-UK Institute for Cancer Research, JEUK Co., Ltd., Gumi, Kyungbuk, Korea.
Kim H; JE-UK Institute for Cancer Research, JEUK Co., Ltd., Gumi, Kyungbuk, Korea.
Yun MR; JE-UK Institute for Cancer Research, JEUK Co., Ltd., Gumi, Kyungbuk, Korea.
Kang HN; JE-UK Institute for Cancer Research, JEUK Co., Ltd., Gumi, Kyungbuk, Korea.
Pyo KH; JE-UK Institute for Cancer Research, JEUK Co., Ltd., Gumi, Kyungbuk, Korea.
Park HJ; JE-UK Institute for Cancer Research, JEUK Co., Ltd., Gumi, Kyungbuk, Korea.
Lee JM; JE-UK Institute for Cancer Research, JEUK Co., Ltd., Gumi, Kyungbuk, Korea.
Choi HM; JE-UK Institute for Cancer Research, JEUK Co., Ltd., Gumi, Kyungbuk, Korea.
Ellinghaus P; Bayer Pharma AG, Global Drug Discovery, Wuppertal, Germany.
Ocker M; Bayer Pharma AG, Global Drug Discovery, Wuppertal, Germany.
Paik S; Division of Pathology NSABP, Pittsburgh, PA, USA.
Kim HR; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Cho BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

Oncogenesis ; 5(7): e241, 2016 Jul 18.

Article en En | MEDLINE | ID: mdl-27429073

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncogenesis Año: 2016 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncogenesis Año: 2016 Tipo del documento: Article